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Previewscurrently in development to target aber-
rant spliceosome function in MDS and
other malignancies, and these models
will be invaluable for pre-clinical testing
of these drugs.
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In this issue ofCancer Cell, Polprasert and colleagues identified recurrent mutations in the DEAD/H-box RNA
helicase gene DDX41 in familial and acquired cases of myelodsyplasia and acute myeloid leukemia. These
mutations induce defects in RNA splicing and represent a new class of mutations in myeloid malignancies.The familial myelodysplastic (MDS)/acute
myeloid leukemia (AML) syndromes
belong to a group of rare inherited disor-
ders that represent a unique resource to
study the initial steps toward leukemia
progression. Recent findings indicate
that AML occurs after a stepwise pro-
cess of genetic and epigenetic changes,
some of which are ancestral and are
found in a preleukemic clone that pre-
cedes the fully transformed AML cells
bearing additional alterations (Pandolfi
et al., 2013). In familial MDS/AML, the
initial germline mutation can be consid-
ered a preleukemic event, required but
not sufficient for leukemia initiation.
Among the most studied ones are familial
AML with mutated CEBPA, familial MDS/
AML with GATA2 mutations, and familial
platelet disorder with predisposition to
AML (FPD/AML) due to RUNX1 muta-
tions (West et al., 2014). Interestingly,
mutations in these transcription factorsalso play important roles in sporadic
AML, showing that, in principle, both
germline and acquired mutations of the
same genes can deregulate the hemato-
poietic compartment and lead to AML
development. Thus, the study of patients
with familial MDS/AML has proven to be
extremely valuable for understanding the
multi-step leukemogenic process (Ant-
ony-Debre´ et al., 2015), including in spo-
radic leukemias.
The advent of whole exome sequencing
technology is of great interest for the
identification of new mutations in familial
MDS/AML syndromes, because the ge-
netic origin of many of them remains
unknown. A better knowledge of these
syndromes would be beneficial not only
for research, but also for clinical care,
as individuals harboring familial muta-
tions could be identified, e.g., for more
frequent follow-up examinations or for
exclusion when a bone marrow allograftis considered. In this issue of Cancer
Cell, Polprasert et al. (2015) identified
functionally relevant mutations in the
gene coding for the DEAD/H-box RNA
helicase DDX41 in both familial and
sporadic MDS/AML cases. Initially, they
discovered inherited DDX41 mutations in
several MDS/AML pedigrees and showed
that additional somatic DDX41 mutations
of the remaining wild-type allele were pre-
sent at MDS/AML diagnosis in half of the
cases (Figure 1A). This is similar to what
has been observed in MDS/AML with
CEBPA or RUNX1 mutations, where bial-
lelic mutations are found with AML pro-
gression (Pabst et al., 2008; Preudhomme
et al., 2009). The clonal architecture of
leukemic clones revealed that acquired
DDX41 mutations could be a founder
event in some patients. Familial DDX41
MDS/AML syndrome was characterized
by a long latency, an advanced stage at
diagnosis (high risk MDS/AML), normall 27, May 11, 2015 ª2015 Elsevier Inc. 609
Figure 1. DDX41 Mutations in Myeloid Neoplasms
(A) DDX41 mutations in familial and acquired MDS/AML. Germline mutations
are consistent with a preleukemic state, whereas acquired mutations,
including in the second allele of DDX41 (found in half of the patients), are
necessary for leukemia initiation. Analysis of the clonal architecture at the
leukemic stage revealed that acquired DDX41 mutations can be ancestral or
be present in a subclone. Abbreviations: AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome.
(B) Association of DDX41 with the spliceosome. Wild-type DDX41 physically
interacts with components of the U2 and U5 small nuclear ribonucleic pro-
tein complexes, and mutation of DDX41 results in disruption of these inter-
actions and splicing defects, including aberrant exon skipping or exon
retention. Abbreviations: ex, exon; DDX41 mut, DDX41 mutated; mRNA,
messenger RNA.
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Previewskaryotype, and a lack of
‘‘typical’’ AML mutations.
This phenotype, the pres-
ence of biallelic mutations,
as well as their recurrence,
were in support of an onco-
genic functional role of
DDX41 mutations.
In addition to familial cases,
the authors found recurrent
DDX41mutations in acquired
myeloid neoplasms (at a fre-
quency of around 1.5%) and
showed an association with
inferior overall survival and
advanced stage of disease
(high risk MDS and AML).
Interestingly, in half of these
patients, theDDX41mutation
was germline. Conceptually
similar findings were previ-
ously described for CEBPA
mutations (Pabst et al.,
2008). These findings sug-
gest that germline initiation/
predisposition of MDS/AML
is currently likely underesti-
mated. Mutations in AML-
associated genes such as
RUNX1 or CEBPA, and now
DDX41 and possibly others,
are detected at AML diag-
nosis, but their germline char-
acter may not be identified in
a considerable number of
cases. Moreover, germlinegene mutations can easily be missed
because of the applied analysis strategies
in many major studies, because mutations
found in both germline and leukemic sam-
ples are often excluded as polymor-
phisms, (falsely) assumed functionally
irrelevant. Somatic DDX41 mutations
have been reported in one previous study
of sporadic AML (Ding et al., 2012). Over-
expression as well as mutations/deletions
of other members of the DEAD/H-box
RNA helicase family have been described
in several other cancers, where they can
act both as tumor suppressors and onco-
genes (Fuller-Pace, 2013). Interestingly,
Polprasert et al. (2015) identifiedmutations
in othermembers of theDEAD/H-boxRNA
helicase family in about 4% of patients in
their cohort, suggesting that RNA helicase
mutations represent anentirenew familyof
mutations in myeloid neoplasms. All heli-
case mutations, including DDX41, were
found to be mutually exclusive. Interest-610 Cancer Cell 27, May 11, 2015 ª2015 Elsingly, DDX41 is located on chromosome
5 and is deleted in 25% of MDS with
del(5q). Patients harboring mutations or
low levels of DDX41 showed a better
response to lenalidomide, even in the
absence of del(5q), suggesting an impor-
tant role of DDX41 in treatment response
and a potential targeted therapy for this
group of patients.
The reduced expression as well as
the presence of DDX41 deletions and
the presence of frameshift mutations in fa-
milial MDS/AML indicated a tumor sup-
pressor function for DDX41 in MDS/
AML. Indeed, the knockdown of DDX41
resulted in increased proliferation and a
differentiation block, whereas its over-
expression decreased cell growth and
enhanced cellular differentiation in cell
lines as well as primary patients’ diseased
cells. Furthermore, DDX41 knockdown
led to an increase in tumor growth in a
xenotransplantation model in vivo.evier Inc.Little is known about the
molecular mechanism/func-
tion of DDX41, and its role
in hematopoiesis is unclear.
Other RNA helicase members
are involved in several pro-
cesses, including in ribosome
biogenesis, pre-mRNA splic-
ing, and translation (Jankow-
sky, 2011). For example, one
member of the DEAD/
H-box protein family, Prp5,
is required for spliceosome
assembly and physically inter-
acts with the U1 and U2 small
nuclear ribonucleic proteins
(snRNPs) (Xu et al., 2004).
Thus, Polprasert et al. (2015)
investigated more closely a
possible association of
DDX41 with spliceosomal pro-
teins. They identified a direct
interaction of DDX41 with spli-
ceosomal components and
showed that DDX41 muta-
tions impaired interactions
with several components of
the U2 snRNP, including
SF3B1, and the U5 snRNP,
includingPRPF8. Investigation
of RNA splicing revealed de-
fects associated with DDX41
mutations with aberrant exon
skipping or exon retention
(Figure 1B). It remains to be
determined exactly how andwhen DDX41 interacts with the spliceo-
some during the splicing process and
whether this new class of mutations could
be part of the spliceosomal-related de-
fects that were recently discovered in
MDS/AML. Spliceosomal mutations can
result in the inactivation of tumor suppres-
sor genes as well as alterations in the bal-
ance of isoforms of genes, with increased
expression of isoforms promoting cell
proliferation. It remains to be explored
whethermutations inDEAD/H-boxprotein
family members may have similar conse-
quences on RNA splicing and promote
leukemia development and progression
through similar mechanisms.
In summary, the study by Polprasert
et al. (2015) shows that functionally rele-
vant mutations of DDX41 and other
members of the DEAD/H-box RNA heli-
case family genes represent a novel
family of mutations in myeloid malig-
nancies with possible implications for
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Previewsprognosis and treatment of MDS/AML.
They can be founder events and are
associated with a preleukemic state.
Further studies of the mechanisms and
functions of DDX41 and other members
of the RNA helicases family in hemato-
poiesis and leukemogenesis are war-
ranted and may ultimately lead to ap-
proaches of therapeutic targeting of
these proteins.
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Emerging evidence is contributing to explain how leukemias disrupt normal blood cell production. In this
issue of Cancer Cell, Welner and colleagues show that, during the development of chronic myeloid leukemia,
mutated cells transform normal hematopoietic progenitors into ‘‘leukemic like’’ cells through IL-6 secretion,
proposing a new cellular target.Classical cancer therapies target the ma-
lignant cells. However, the environment
surrounding the tumors, referred to as
‘‘niche,’’ during cancer development and
progression is gaining increased atten-
tion. Many efforts are now directed to-
ward understanding the relationships
between the tumor and its supporting
cells (e.g., stromal cells), which have
become a novel target for therapies.
This also applies to blood proliferative
disorders, such as myeloproliferative
neoplasms (MPNs), in which the interac-
tions between tumoral and stromal cells
are critical for disease progression both
at the hematopoietic stem cell (HSC) and
progenitor level (Arranz et al., 2014;
Krause et al., 2013; Schepers et al.,
2013). However, leukemic stem cell
niches might be different in chronic and
acute myeloid leukemias. The Scaddengroup has demonstrated that activation
of osteoblastic cells by parathyroid
hormone attenuates chronic myeloge-
nous leukemia (CML), but enhances
instead MLL-AF9 oncogene-induced
acute myeloid leukemia (Krause et al.,
2013).
Using a JAK2V617F murine model, we
have recently shown that nestin+ mesen-
chymal stem cells (MSCs) play a pivotal
role in regulating the proliferation of
mutant MPN HSCs. IL-1b secreted by
mutant HSCs induces neural damage to
the niche, leading to a marked reduction
in nestin+ MSCs, uncontrolled mutant
HSC proliferation, and subsequent dis-
ease progression (Arranz et al., 2014).
Bone marrow stromal cells have been
proposed to secrete factors that protect
JAK2V617F cells from JAK2 inhibitors
(Manshouri et al., 2011). Additionally, thePassegue´ group has recently demon-
strated that CML cells induce expansion
of osteoblastic precursors that poorly
support normal hematopoietic progeni-
tors (Schepers et al., 2013).
CML is an MPN that originates in a
mutated hematopoietic stem/progenitor
cell (HSPC) carrying the t(9;22)(q34;q11)
translocation. This mutation leads to
the expression of the BCR/ABL fusion
protein, a constitutively active tyrosine
kinase that promotes the growth of
mutated HSCs and their progeny. In hu-
mans, CML presents first with a chronic
phase in which differentiated myeloid
cells accumulate. This is followed by a
short accelerated phase that precedes a
rapid blast phase when symptoms aggra-
vate as myeloid cells fail to mature and
fully differentiate (Savona and Talpaz,
2008).l 27, May 11, 2015 ª2015 Elsevier Inc. 611
